May, 3rd – 4th 2018
Department of Drug Sciences and Clinical Pharmacology, University
Ambramson Cancer Center, Perelman School of Medicine at the University
Philadelphia, Pennsylvania (US)
Department of Hematology, Jagellonian University
Cardio-Oncology is a rapidly expanding discipline that focuses on the cardiovascular performance of patients treated with anticancer drugs.
It was born to oncologists and cardiologists but quickly involved hematologists, pediatricians and gerontologists, not to mention epidemiologists and preclinical scientists.
There are different approaches one may adopt in addressing cardio-oncology. Some believe that cardio-oncology should be a meticulous deciphering and listing of cardiovascular toxicities induced by anticancer drugs. This is in the focus by definition but introduces potential biases that eventually lead doctors to question benefit from some antitumor drugs. Others believe that cardio-oncology should always be guided by a thoughtful analysis of risk: benefit ratio, such that patients eventually receive optimal life-saving treatments while also receiving an adequate cardiovascular surveillance or prophylaxis. We definitely like this second approach better and that is why we invite you to attend a “Colloquium” that is conceived to be an interactive think tank. The Program is self explanatory and goes in that direction.
This Colloquium follows on the International Workshop on Anthracycline Cardiotoxicity that was held in Como back in 2006, and the First International Colloquium on Cardio-Oncology that was held in Rome, 2014. All such events were made possible by the generosity and foresight of Menarini Foundation, which I thankfully acknowledge.
Collegium Novum – Jagellonian University
Gołębia 24, 31-007 Kraków, Poland
Bastioni di Porta Volta, 10 – 20121 Milano (Italy)
Phone: +39 02 81838120 – Cell: +39 3209066533 – Fax: +39 02 87181580
email@example.com – www.congresslab.it